Abstract: This disclosure provides a chemically modified induced pluripotent stem (iPS) cells characterized by DNA hypomethylation and methods for generating the cells. The cells are useful in method for or regenerating cardiac muscle tissue or to promote the replacement of cardiac scar tissue in a patient in need thereof and to treat cardiac disease.

Abstract: A method for degrading Rhodamine B including: mixing BiOBr and Rhodamine B; and irradiating the mixture with a radiation having a wavelength of from 440 nm to 554 nm. The Rhodamine B may be in an aqueous solution. The BiOBr may be added to the aqueous solution of Rhodamine B in an amount of from 0.2 to 0.5 mg/ml. The BiOBr may have a sheet-like structure with particles having a diameter of from 3 ?m to 5 ?m. The BiOBr may be in a pure crystal tetragonal phase.

Abstract: Provided herein are methods and devices for rapidly and accurately heating fluid droplets surrounded by a gas-phase medium, such as air. Sub-nanoliter fluid droplets can be rapidly heated by nanoscale field effect transistors via microwave heating by an applied AC voltage to the FET. The heating is in a well-defined interior portion of the fluid droplet, with minimal heating of the outer portion of the fluid droplet, thereby minimizing evaporation. In this manner, rapid thermal cycling is possible, including independently and in parallel for a plurality of droplets. Accordingly, the methods and devices provided herein are used in point-of-care detection such as by PCR that is high speed, robust and of low cost.

Abstract: The present invention provides coated tablet formulations comprising neratinib maleate, and improved methods for making such coated tablets.

Abstract: The present invention provides coated tablet formulations comprising neratinib maleate, and improved methods for making such coated tablets.

Abstract: The present invention provides coated tablet formulations comprising neratinib maleate, and improved methods for making such coated tablets.

Abstract: The present invention provides coated tablet formulations comprising neratinib maleate, and improved methods for making such coated tablets.

Abstract: A method and an apparatus provide intelligent monitoring and maintenance of a system. The method according to one embodiment accesses data relating to functional components of the system; extracts parameter information for functional components of the system, the step of extracting parameter information including performing inferential processing and trend recognition of the data using previous knowledge about the system, and simulating performance of the system using models of the system and previous knowledge about the system; identifies new information about the system present in extracted parameter information; and provides the new information to the step of extracting parameter information, to be used as previous knowledge.

Abstract: The present invention provides an amorphous form of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid. This invention also provides processes for preparing the amorphous form and pharmaceutical compositions including the amorphous form.

Abstract: A CCI-779 oral dosage form is provided in which, after oral administration to a subject, the CCI-779 has a whole blood peak concentration (Cmax) of 5.4±1.8 ng/mL and an area under the curve (AUC) of about 66± about 22 ng-hr/ml and the sirolimus has a Cmax of 18.7±9.6 ng/mL and an AUC of about 600± about 228 ng-hr/ml, for a 25 mg unit dose of CCI-779. Another CCI-779 oral dosage form is provided which, after oral administration thereof to a subject, the CCI-779 has a Cmax of 5.7±1.7 ng/mL and an AUC of about 60± about 20 ng-hr/ml and the sirolimus has a Cmax of 17.1±8.1 ng/mL and an AUC of about 548± about 187 ng-hr/ml in whole blood, for a 25 mg unit dose of CCI-779. Products containing these oral dosage forms, and methods of use thereof, are also described.

Abstract: The present invention provides an amorphous form of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid. This invention also provides processes for preparing the amorphous form and pharmaceutical compositions including the amorphous form.

Abstract: The present invention provides an amorphous form of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid. This invention also provides processes for preparing the amorphous form and pharmaceutical compositions including the amorphous form.

Abstract: A CCI-779 oral dosage form is provided in which, after oral administration to a subject, the CCI-779 has a whole blood peak concentration (Cmax) of 5.4±1.8 ng/mL and an area under the curve (AUC) of about 66±about 22 ng-hr/ml and the sirolimus has a Cmax of 18.7±9.6 ng/mL and an AUC of about 600±about 228 ng-hr/ml, for a 25 mg unit dose of CCI-779. Another CCI-779 oral dosage form is provided which, after oral administration thereof to a subject, the CCI-779 has a Cmax of 5.7±1.7 ng/mL and an AUC of about 60±about 20 ng-hr/ml and the sirolimus has a Cmax of 17.1±8.1 ng/mL and an AUC of about 548±about 187 ng-hr/ml in whole blood, for a 25 mg unit dose of CCI-779. Products containing these oral dosage forms, and methods of use thereof, are also described.

Abstract: Micronized CCI-779 is described. This directly compressible rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid provides a convenient and effective method to deliver therapeutic levels of CCI-779 to a patient.

Abstract: Solid, pharmaceutical dosage forms of [2-(8,9-dioxo-2,6-diazabicyclo [5.2.0]non-1(7)-en-2-yl)alkyl]phosphonic acid and derivatives thereof are disclosed. In addition, methods of use are disclosed for the treatment, inter alia, of cerebral vascular disorders, anxiety disorders; mood disorders; schizophrenia; schizophreniform disorder; schizoaffective disorder; cognitive impairment; chronic neurodegenerative disorders; inflammatory diseases; fibromyalgia; complications from herpes zoster; prevention of tolerance to opiate analgesia; withdrawal symptoms from addictive drugs; and pain.

Abstract: The present invention provides an amorphous form of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid. This invention also provides processes for preparing the amorphous form and pharmaceutical compositions including the amorphous form.

Abstract: This invention provides solid oral formulations of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779).